Please login to the form below

Not currently logged in
Email:
Password:

TEVA's tardive dyskinesia drug wins FDA breakthrough status

SD-809 to be given development incentives
TEVA

TEVA's tardive dyskinesia drug, SD-809 has been granted breakthrough therapy designation by the FDA.

The designation comes on the back of data from the phase II/III Aim to Reduce Movements in Tardive Dyskinesia (ARM-TD) study which enrolled 117 patients with moderate to severe degrees of the condition.

Michael Hayden, president of global R&D and chief scientific officer at TEVA, said: “The granting of breakthrough therapy designation by the FDA represents significant progress toward advancing the clinical program for SD-809, as a potential, much-needed treatment option for the underserved tardive dyskinesia patient population.

“We remain excited about studying this innovative compound across a number of indications.”

Tardive dyskinesia is a condition characterised repetitive and uncontrollable movements of the tongue, lips, face and extremities and has been associated with the use of anti-psychotic drugs.

The condition affects around 500,000 people in the United States.

Breakthrough Therapy Designation is granted to a drug that is intended to treat a serious condition and preliminary clinical evidence suggests that SD-809 (deutetrabenazine) may demonstrate substantial improvement over available therapy. 

Article by
Nikhil Patel

10th November 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics